Cyclododeca-1,5,9-triene

Repeated dose toxicity: inhalation

Administrative data

Endpoint:

short-term repeated dose toxicity: inhalation

Adequacy of study:

other information

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference

Reference 1

Title:

No information

Author:

DuPont Co. (1965). Unpublished Data, Haskell Laboratory Report No. 187-65; cited in DuPont Safety, Health & Environmental Excellence Center, Wilmington (Del., USA); Robust summary for 1,5,9-cyclododecatriene (revised).U.S. EPA, 46 pp (2003)

Reference 2

Reference Type:

publication

Title:

Robust summary for 1,5,9-cyclododecatriene (revised).

Author:

DuPont Safety, Health & Environmental Excellence Center, Wilmington (Del., USA)

Year:

2003

Bibliographic source:

U.S. EPA, 46 pp

Materials and methods

Principles of method if other than guideline:

Method: other: see reference

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

1,5,9-cyclododecatriene

IUPAC Name:

1,5,9-cyclododecatriene

Details on test material:

purity: 99.8%

Test animals

Species:

rat

Strain:

other: Crl:CD

Sex:

male

Details on test animals or test system and environmental conditions:

-during exposure rat were housed individually in stainless wire mesh compartments
-following each exposure rats were housed individually
-Weight at study initiation: 230-270 g

Administration / exposure

Route of administration:

inhalation

Type of inhalation exposure:

whole body

Vehicle:

air

Remarks on MMAD:

MMAD / GSD: no data

Details on inhalation exposure:

ADMINISTRATION / EXPOSURE 
- Type of exposure: whole body, aerosol
- Post exposure period: none
- Doses: 1.64 mg/l
- Particle size: not reported
- Type or preparation of particles: spray nozzle with precision liquid  metering pump
- resulting aerosol mist was directed into the main airstream entering the exposure chamber

Analytical verification of doses or concentrations:

not specified

Details on analytical verification of doses or concentrations:

no data

Duration of treatment / exposure:

6 hours/day, 10 days

Frequency of treatment:

daily

Doses / concentrations

Remarks:

Doses / Concentrations:
1.64 mg/L
Basis:
nominal conc.

No. of animals per sex per dose:

20

Control animals:

no

Details on study design:

Post-exposure period: none

Positive control:

not reported

Examinations

Observations and examinations performed and frequency:

CLINICAL OBSERVATIONS AND FREQUENCY: 
- Clinical signs: at intervals throughout each exposure period
- Body weights were recorded
- Necropsies were performed

Sacrifice and pathology:

Necropsies performed and tissue sections preserved for histopathological examinations: lung, liver, spleen, kidneys, bone marrow , brain

Results and discussion

Results of examinations

Details on results:

TOXIC RESPONSE/EFFECTS BY DOSE LEVEL: 
- Mortality and time to death: no deaths
- Clinical signs: Peripheral vasodilation was noted throughout the study.  A slight twitching only at the beginning of each exposure period through  days 3 to 10 was observed. A lack of activity was observed throughout  each exposure period.
- Body weight gain: Normal
- Gross pathology: The tissues of the major organs appeared normal at the  terminal autopsy.
-substance did not produce any distinctive histological alterations in brain, lung , liver and bone marrow of the male albino rats
-only possible significant alteration is described as increased intracytoplasmatic granularity of renal proximal tubule epithelium but because of non- specific variable appearence of tubule alteration the difference was a rather inconsistent degree of granularity which was difficult to attribute to the test substance 1,5,9 cyclododecatriene

Target system / organ toxicity

Critical effects observed:

not specified

Any other information on results incl. tables

no further information